GENE ONLINE|News &
SynbioTech Redefines Probiotics With a Research-Driven CDMO Platform
“We do not want to provide only a raw material or a single product,” Sean Yang, Chief Operating Officer at SynbioTech added. “We aim to deliver a complete solution.” Image: GeneOnline
SynbioTech is emerging as a key player in the next-generation probiotic industry as global demand shifts toward functional, science-backed, and personalized wellness solutions. Competition is no longer centered on individual strains alone. Instead, companies are increasingly differentiated by their ability to integrate R&D, formulation science, manufacturing, and commercialization into scalable platforms.
With operations spanning strain development to finished-product manufacturing, SynbioTech has evolved beyond traditional probiotic production into a research-driven CDMO platform. The company combines proprietary technologies, stability optimization capabilities, and clinically oriented development strategies to support partners across multiple health and nutrition categories.
In an exclusive interview with GeneOnline, Sean Yang, Chief Operating Officer at SynbioTech, discussed how the company is building a differentiated position within the global probiotic supply chain through integrated R&D capabilities and application-focused innovation.
Global Probiotic Trends Are Driving Demand for CDMO Partners
Population aging continues to accelerate worldwide. At the same time, consumers now have easier access to health information than ever before. Digital tools, including artificial intelligence and large language models, have further increased transparency across the healthcare and nutrition industries. As a result, consumers are becoming more selective about product quality, scientific evidence, and personalized health solutions. These shifts are reshaping the probiotic market.
According to Yang, four major industry trends now define the sector.
- Functional Applications and Consumer Segmentation
Traditional “one product for all ages” positioning is gradually disappearing. Product development is increasingly segmented by age group, lifestyle, and health goals. Companies now design targeted formulations for children, adults, seniors, athletes, and consumers seeking specific benefits such as fatigue reduction, gut health, weight management, or metabolic support.
“The era of one probiotic product for the whole family is fading,” Yang said. “The market is splitting into many smaller application-driven categories based on age, lifestyle, and purpose.” This transition reflects a broader movement from mass-market wellness products toward personalized and precision-oriented health solutions.
- Rising Quality Standards and Science-Backed Products
Consumers now actively search for clinical evidence and scientific validation before purchasing health supplements. Greater transparency across digital platforms has increased expectations for product efficacy, safety, and manufacturing quality.
As a result, products supported by clinical studies and mechanistic research are gaining stronger market acceptance. Companies are also investing more heavily in human studies, mechanism validation, and formulation science.
- Asia Is Becoming the New Growth Engine for Global Wellness
The overall probiotic and health supplement market continues to grow steadily. However, the center of growth is shifting away from North America and Europe toward Asia.
Countries across Northeast and Southeast Asia are experiencing rapid expansion, driven by aging populations, rising disposable income, and stronger health awareness. Many regional markets are now achieving double-digit compound annual growth rates.
“When we include China, the Asian market has already surpassed North America in scale,” Yang noted. “More importantly, it still has very strong growth momentum.”
- Competition Has Expanded Beyond Strains
The industry initially competed at the species level, then moved toward strain-level differentiation. Today, companies must go even further.
Current competition increasingly focuses on delivery systems, formulation technologies, and targeted applications. The goal is no longer simply to identify a probiotic strain. Companies must ensure that strains reach the correct physiological targets and support specific health indications under real-world conditions. This shift is pushing the industry toward integrated healthcare solutions rather than standalone probiotic ingredients.
As probiotics evolve from individual ingredients into comprehensive health solutions, commercialization has become increasingly complex. Success depends not only on scientific innovation, but also on the ability to integrate scientific validation, formulation technologies, manufacturing expertise, regulatory knowledge, supply chain management, and market strategy. This growing complexity is driving demand for platform-based CDMOs that can connect these capabilities and accelerate the journey from discovery to commercialization. In this context, CDMO value is no longer limited to production capacity; it is increasingly defined by the ability to turn probiotic science into market-ready health solutions.
Why the Probiotic Industry Increasingly Needs CDMOs
Under these evolving market conditions, Yang believes the industry is moving beyond the traditional CDMO model toward platform-based partnerships that support the entire commercialization journey. Rather than functioning solely as manufacturers, modern CDMOs are increasingly expected to act as commercialization platforms that integrate scientific development, regulatory strategy, manufacturing, and market execution into a single continuum.
SynbioTech, for example, positions itself as a commercialization platform that enables this full-spectrum support through three distinct pathways. For companies seeking to enter new health categories, the process begins with consumer and market insights, followed by support across formulation design, dosage form development, regulatory planning, manufacturing, and commercialization strategy.
Meanwhile, brands prioritizing speed-to-market can leverage ready-to-launch solutions built on validated formulations and established technology platforms, significantly shortening development timelines and reducing commercialization risks.
For organizations that already possess proprietary strains or intellectual property, the company offers a collaborative development pathway. These partners include research institutions, universities, biotech startups, and established companies. The goal is to unlock the full commercial potential of these assets. Through its integrated advisory and technical platform, clients can leverage SynbioTech’s expertise.
These examples reflect a broader structural shift in the industry: commercialization is no longer a downstream step but a core bottleneck in probiotic innovation. As products become increasingly sophisticated, companies must ensure that strains not only demonstrate efficacy in laboratory conditions but also maintain viability and functional performance through formulation, manufacturing, distribution, and real-world use. This requires capabilities that extend well beyond traditional production.
As a result, CDMOs are evolving into essential integration hubs within the probiotic ecosystem. “CDMOs simplify the ecosystem into two key roles,” Yang explained. “One side focuses on branding and market strategy. On the other side, companies like SynbioTech transform those ideas into commercially successful products.” He emphasized that this transformation requires more than manufacturing capacity alone, but also deep R&D capabilities, strain resources, and end-to-end control of critical inputs.
This philosophy is reflected in SynbioTech’s guiding principle: “From Strain to Solution.”
“We do not want to provide only a raw material or a single product,” Yang added. “We aim to deliver a complete solution.”
“Unlike companies that focus primarily on strain supply or contract manufacturing, SynbioTech integrates strain resources, clinical validation, formulation science, manufacturing technologies, and commercialization support within a single development platform. “
SynbioTech TWK10®: Beyond Sports Nutrition
The global probiotic industry includes many century-old companies with extensive clinical portfolios and countless commercial strains. Yet SynbioTech managed to stand out with TWK10®, a differentiated strain originally isolated from traditional Taiwanese pickled cabbage.
TWK10® is positioned as a multifunctional strain targeting healthy aging and muscle function maintenance, with additional relevance in exercise performance. It was initially developed to address mobility decline in aging populations, as SynbioTech researchers observed that reduced physical activity is closely associated with declines in muscle strength, functional capacity, and overall healthspan in older adults. This established TWK10® ‘s core positioning around aging-related muscle and functional health.
Building on this foundation, TWK10® has been further explored in more specific application contexts. One key extension is sarcopenia and age-related muscle loss, a growing public health challenge in rapidly aging societies where maintaining muscle mass and physical function is increasingly critical for quality of life. Beyond aging alone, TWK10® also holds potential for women’s health across different life stages, as hormonal changes throughout life may influence muscle composition, energy metabolism, and physical resilience.
TWK10® belongs to the species Lactiplantibacillus plantarum. However, it demonstrated distinct physiological characteristics during early-stage screening. Yang revealed that researchers initially observed larger cell size, thicker cell walls, and stronger antioxidant capacity at the cellular level. Subsequent animal studies further showed improved exercise performance compared with control groups.
Mechanistically, TWK10® appears to modulate gut microbiota composition and increase short-chain fatty acid production. This may help reduce fatigue-associated biomarkers such as lactate and ammonia while supporting energy metabolism and physical performance. Clinical studies have also demonstrated improvements in muscle strength among older adults.
“In the rapidly growing postbiotics field, we also discovered that inactivated TWK10-derived postbiotics can maintain similar functional benefits,” Yang said. “This helps overcome some of the formulation limitations associated with live probiotics.” The company is currently further evaluating the potential of postbiotic formulations for aging and women’s health applications.
TWK10® has already achieved several regulatory and commercial milestones. In Taiwan, it became the first probiotic product to receive the “anti-fatigue” Health Food certification mark. In South Korea, it was the first Lactiplantibacillus plantarum strain approved for claims related to fatigue reduction and exercise performance enhancement. The strain has also obtained Food with Function Claims (FFC) recognition in Japan.
SYNTEK®: An Integrated Technology Platform Across the Probiotic Value Chain
As consumer expectations for probiotic products continue to rise, efficacy is no longer defined solely by strain selection. End users increasingly expect consistent, visible functional outcomes from every intake, placing greater pressure on brands to ensure reliable product performance.
This, in turn, shifts the burden upstream to probiotic brands and manufacturers, who must ensure that ingredients remain stable, viable, and effective throughout formulation, production, distribution, and storage. However, maintaining consistent quality across these stages remains one of the most persistent challenges in the industry, particularly as probiotics are highly sensitive to temperature, humidity, and formulation compatibility with other active ingredients such as vitamins, minerals, and botanical compounds.
To address these challenges, companies increasingly rely on advanced probiotic ingredient platforms and manufacturing technologies, such as SynbioTech’s proprietary SYNTEK® system. More than a stability system, SYNTEK® reflects SynbioTech’s integrated probiotic manufacturing technology platform that combines strain screening, fermentation optimization, functional enhancement, coating technology, freeze-drying, and quality control. By improving strain robustness and preserving viable cell counts throughout the production process, the platform helps transform probiotic science into stable, scalable, and commercially viable formulas. This integrated approach allows brands to accelerate product development while maintaining product quality and performance across diverse applications.
Beyond stability, formulation compatibility is another critical barrier in product development. Many probiotic strains must coexist with multiple active ingredients without losing functionality or triggering antagonistic interactions. It addresses this by enhancing strain resilience, supporting the development of stable and compatible probiotic formulas for dietary supplements and functional food systems.
Yang also noted that regional adaptation plays an increasingly important role in product performance. Many imported probiotic products are designed around Western dietary patterns and microbiome profiles, which may not always reflect the dietary habits, microbiome characteristics, and consumer preferences found across Asian markets. This creates opportunities for locally developed platforms such as SYNTEK®, which can be adapt to regional consumer needs and market conditions.
“In the CDMO industry, quality, manufacturing capacity, and delivery capability are basic requirements,” Yang said. “The real differentiator is research capability.”
Expanding Across Asia While Building Global Differentiation
SynbioTech continues to strengthen its presence throughout Asia, with strategic focus areas including healthy aging, women’s health, and metabolic wellness. The company also emphasizes flexible and consultative customer support.
In Western markets, SynbioTech continues expanding through differentiated products such as TWK10®. Beyond R&D investment and manufacturing quality, Yang also highlighted the company’s emphasis on supply chain transparency.
“Our systems cover both manufacturing process management and product traceability,” he said. “Clients can visit our facilities at any time without advance appointments. This helps Taiwanese customers manage quality and operational risks more effectively and more efficiently.”
The company has also implemented carbon footprint tracking and disclosure systems in response to growing ESG expectations across the healthcare supply chain.
Taiwan’s Fermentation Industry Holds a Strategic Advantage
When discussing Taiwan’s role in the global microbial and fermentation industry, Yang believes the country possesses highly unique advantages.
“Fermentation is very different from industries that depend heavily on land or large-scale natural resources,” he explained. “It relies more on precision manufacturing, industrial management, and advanced talent. Those are all areas where Taiwan has accumulated long-term strengths.”
Unlike many raw material industries that rely heavily on imports, Taiwan maintains a high degree of self-sufficiency in fermentation and microbial products. Local suppliers account for more than 80% of the domestic market.
“I personally believe microorganisms could become one of Taiwan’s most internationally competitive biotech specialties,” Yang said.
A One-Stop CDMO Platform for the Probiotics Industry
“We want good research to move beyond the laboratory,” Yang said. “It should ultimately reach the market and become part of consumers’ daily lives.” For Yang, SynbioTech’s mission extends far beyond probiotic manufacturing alone.
As global healthcare supply chains continue to reorganize and consumer demand becomes increasingly segmented, SynbioTech represents more than the growth story of a single probiotic company. It reflects the broader evolution of Taiwan’s microbial industry—from contract manufacturing toward integrated R&D, formulation science, and global commercialization.
In an era defined by highly selective consumers and increasingly diversified health demands, companies like SynbioTech may represent Taiwan’s most sustainable competitive path. Rather than competing through scale alone, they are building differentiated value through deep technical expertise, integrated CDMO services, and long-term R&D investment.
LATEST
EVENT
2026-08-07
Healthy Ageing Tech Show (7-9 Aug, TAIPEI WTC) (Longevity, elder care & ageing tech)
Taipei, Taiwan
